New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections
February 2011
New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections.
A beta-lactam (cephalexin, etc) USED to cover both purulent skin infections due to staph and cellulitis due to strep.
But now many purulent skin infections are due to community-acquired methicillin-resistant Staph aureus (CA-MRSA) and therefore are resistant to beta-lactams.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive